Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Complete genomes of the hydrogenotrophic methanogen species -Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1

Humm E, Chettiyar R, Rubbi L, Del Vecchio G, Pellegrini M, Ha SM, Gunsalus RP. Complete genomes of the hydrogenotrophic methanogen species-Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1.[...]

SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement

Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J,[...]

A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the Dermatology Match Process

D'Amiano AJ, Rohr B, Glick B, Hogeling M, Keller M, Sunshine J. A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the[...]